Solace Therapeutics Inc.
Reversible, office-based SUI solution
This article was originally published in Start Up
Solace Therapeutics Inc.’s Solace Bladder Control System is a small, lightweight, polyurethane balloon device that fills with air once it is placed within the bladder, where it floats unobtrusively at the top of the organ, not blocking the urethra. The device is designed to eliminate or reduce involuntary urinary leakage by acting as a “shock absorber” to reduce the temporary peak pressure changes in the bladder that cause urinary leakage.
You may also be interested in...
Angel- and venture-backed medtech start-ups are working to fill the tremendous unmet need for alternative device options for treating (not just managing) female urinary incontinence a condition that has a significant impact on quality of life for millions of women. In this issue we profile Floelle, InControl Medical, NexHand, and Solace Therapeutics.
Alvotech and US marketing partner Teva can now launch “imminently” their long-planned rival to Humira, with the firms believing that the Simlandi biosimilar will stand out from the crowd of other adalimumab challengers thanks to a unique combination of product attributes.
Daiichi Sankyo will expand its production site in Pfaffenhofen, Germany with new R&D capability for antibody-drug conjugates, spending €1bn. Behind the major new investment, the firm has recently filed for the approval of two ADCs in the US and is preparing global approval filings including in Europe and Asia.